Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | VEGFA | P15692 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613593 | 0.91 | PTGDR2 (0.42) | PTGDR2RORCVEGFAEGLN1SETD7 | |
| SCHEMBL21368973 | 0.91 | PTGDR2 (0.42) | PTGDR2RORCVEGFAEGLN1SETD7 | |
| SCHEMBL19785977 | 0.90 | PTGDR2 (0.37) | PTGDR2RORCSETD7SPR | |
| SCHEMBL19785967 | 0.86 | PTGDR2 (0.43) | PTGDR2RORCCCR1 | |
| SCHEMBL17304394 | 0.85 | PTGDR2 (0.45) | PTGDR2RORCVEGFAEGLN1CCR1 | |
| SCHEMBL15776880 | 0.85 | PTGDR2 (0.45) | PTGDR2RORCVEGFAEGLN1CCR1 | |
| SCHEMBL15784144 | 0.85 | PTGDR2 (0.45) | PTGDR2RORCVEGFAEGLN1CCR1 | |
| SCHEMBL29613547 | 0.85 | PTGDR2 (0.45) | PTGDR2RORCVEGFAEGLN1CCR1 | |
| SCHEMBL17182268 | 0.82 | ALDH1A1 (0.43) | PTGDR2RORC | |
| SCHEMBL29613558 | 0.82 | ALDH1A1 (0.43) | PTGDR2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10934282-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | LEO PHARMA A/S (DK) | 2021-03-02 | — | — | US | disclosed |
| US-20200291010-A1 | HETEROAROMATIC MDOULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA A/S | 2020-09-17 | — | — | US | disclosed |
| EP-3484880-B1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA AS (DK) | 2020-09-02 | — | — | EP | disclosed |
| US-10662181-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | LEO PHARMA A/S (DK) | 2020-05-26 | — | — | US | disclosed |
| US-20190284177-A1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA A/S (DK) | 2019-09-19 | — | — | US | disclosed |
| WO-2018011201-A1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | LEO PHARMA A/S (DK) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291010-A1 | HETEROAROMATIC MDOULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | RXRA, RORA, NR1H3 | PTGDR2 328/4885RORC 18/4885VEGFA 2676/4885 |
| US-10934282-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | RXRA, RXRG, RXRB | PTGDR2 434/4885RORC 17/4885VEGFA 2202/4885 |
| US-10662181-B2 | Heteroaromatic modulators of the retinoid-related orphan receptor gamma | RXRA, RXRG, RXRB | PTGDR2 434/4885RORC 17/4885VEGFA 2202/4885 |
| US-20190284177-A1 | HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMA | RXRA, RXRG, RXRB | PTGDR2 434/4885RORC 17/4885VEGFA 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.